EXEL

Exelixis Stock Price

23.07
-0.90 (-3.75%)
Upgrade to Real-Time
Regular Market
23.07

Low
18.18

52 Week Range

High
27.90

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Exelixis Inc EXEL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.90 -3.75% 23.07 11:14:35
Open Price Low Price High Price Close Price Prev Close
23.76 23.03 23.84 23.97
Bid Price Ask Price Spread News
23.05 23.07 0.02 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,996 369,243 $ 23.44 $ 8,654,914 1,515,640 18.18 - 27.90
Last Trade Time Type Quantity Stock Price Currency
11:14:35 6 $ 23.07 USD

Exelixis Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 7.22B 313.10M 277.09M $ 987.54M $ 81.97M 0.35 70.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 966.59k 1.90%

more financials information »

Exelixis News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical EXEL Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week24.7925.0423.0324.341,426,079-1.72-6.94%
1 Month23.7025.1922.6724.131,398,844-0.63-2.66%
3 Months22.7825.1920.8622.971,761,3960.291.27%
6 Months21.0025.6618.1821.872,094,7622.079.86%
1 Year25.8627.9018.1822.892,162,808-2.79-10.79%
3 Years22.5127.9013.4220.512,996,3720.562.49%
5 Years4.6632.504.6519.423,541,83818.41395.06%

Exelixis Description

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.


Your Recent History
NASDAQ
EXEL
Exelixis
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.